Effects of Magnesium Di-Potassium EDTA Suppositories on Blood Chemistry Values
ABSTRACT: Two studies were completed using 21 and 16 patients respectively measuring the effects of Magnesium Di-Potassium EDTA suppositories on standard blood chemistry values. Liver enzymes remain unchanged. BUN/creatinine ratios, bilirubin levels and prothrombin times all showed normalization towards optimal values whether initially high or low. 92% of the subjects had an increase in CO2 levels indicating increases in metabolism. We conclude that Magnesium Di-Potassium EDTA suppositories are absorbed, safe and effective.
Methods and Materials
21 subjects had their blood drawn. Immediately thereafter, they inserted one 333 mg Magnesium Di-Potassium EDTA suppository rectally. 30 minutes later their blood was drawn again. Subjects were told not to change their lifestyle or eating habits. The subjects were then given ten more suppositories and were told to take one per night for ten nights. 11 days later the subjects had their blood drawn again. Some clients had their blood drawn on the12th day and they were given 2 extra suppositories. Of the 21 subjects initially begun with, 5 did not take a second blood draw. One patient revealed that he was on the antibiotic Cipro for a sinus infection, one patient was stung by a jellyfish, one subject began supplementation along with the chelation, one client found the chelation uncomfortable and did not continue and a final patient was not eligible for long term studies since he had already undergobe Chelation Therapy previously. A standard blood chemistry was done along with measurements of phosphorous, uric acid, prothrombin time and lipid profiles. 333 mg of Magnesium Di-Potassium EDTA yields the same amount of EDTA as 303.8 mg of Di-sodium EDTA. Ten suppositories therefore have the same amount of EDTA as a 3.03 gram I.V. of Di-sodium EDTA.
Figures 1 and 2 show the normalizing effect of the suppository form of Magnesium Di-Potassium EDTA on kidney function. Figures 3 and 4 show that there is no stress to the liver as measured liver enzymes remaining stable. Figure 5 shows a normalizing effect on prothrombin time. Figure 6 shows a global increase in the blood CO2 levels indicating an increase of oxygenation and an increase in metabolic efficiency. Figure 7 shows a normalizing effect on bilirubin.
Figures 1 and 2 BUN/Creatinine ratios (10 days)
Figure 1 shows the change in BUN/creatinine ratios after 10 days. The X-axis represents the original BUN/creatinine ratio; the Y-axis represents the change in that ratio after the Magnesium Di-Potassium EDTA. Figure 2 is the same data with the non-conforming data-point removed. This client’s BUN went from 30 to 18 and her creatinine went from 1.2 to 0.7. While this does not yield a change in the BUN/creatinine ratio it obviously implies an incredible regeneration of kidney function in a short period of time.
Figure 3 SGOT levels (10 days) Figure 4 SGPT levels (10 days)
Figure 5 Prothrombin time (30 minutes) Figure 6 Bilirubin levels (10 days)
The X-axis represents the PT time and the Y-axis represents the change in pre and post values.
Prothrombin time tests were performed using the ProTime microcoagulation
system (ITC, Edison, NJ) point of care monitor.
Figure 7 CO2 levels (10 days) Figure 8 Sodium levels (10 days)
In redesigning both the method of administration and the type of ingredient used in chelation, there are two questions to answer. Is it safe, and is it effective? Figures 1 and 2 show that not only is there no apparent damage to the kidney function, there is actually an improvement as measured by the normalization of the BUN/creatinine ratios. Low values moved higher and the high values dropped lower. In addition, the farther from the norm the values initially were, the greater the change seen towards the norm. I.V. chelation also shows this normalizating effect1 but typically only after an initial and reversible glomerulonephritis. We believe that the smaller and more frequent application of suppository EDTA is safer on the kidneys than the less frequent but more intense therapies given intravenously as evidenced here. Figures 3 and 4 show no effect on liver enzymes, further indication of the safety of this protocol.
Figure 5 shows a normalizing effect on prothrombin time after one suppository. Low values moved up and high values moved down. Similar to the BUN/creatinine tests, the farther from the norm the initial values were, the greater the change towards normal. The initial values of the PT time, while higher than normal in both pre and post, are appropriate for the device and analyate used. The point to which the protocol drove the post values is higher than considered normal for the device, but considering that coagulation accounts for the first and third causes of death in this country (heart attacks and strokes) this norm value may not be the optimal value for health. A higher value like the one achieved with this protocol may be preferable.
Figure 6 shows a normalizing effect on the total bilirubin levels. Similar to the BUN/creatinine and prothrombin tests, the farther from the norm the initial values were, the greater the change towards normal. High bilirubin levels indicate excessive breakdown of hemoglobin and/or biliary obstruction. While the literature is silent regarding low bilirubin, we suspect this may be indicative of spleenic, liver or bone marrow dysfunction since bilirubin is the end-product of hemoglobin breakdown by these sites.
Figure 7 shows an increase in the CO2 levels in 93.75% of the subjects. The average increase was 3.125 mEq/L. The average CO2 level of the subjects went from 24.625 mEq/L to 27.75 mEq/L. While reference ranges for CO2 are 23 to 29, optimal values are 26 to 312 with 28.5 being the center-point. to In human metabolism, food and oxygen are combusted to release energy water and carbon dioxide. Since none of the subjects changed their eating patterns, an increase in CO2 means greater oxygen use and more efficient metabolism. It is not a matter of absorbing more oxygen from the air since for most people, pulse oximetry will show near saturation of the hemoglobin with oxygen. Rather it indicates that the oxygen that the clients already had in their blood was now being more efficiently delivered to the tissues. This increase of metabolism and oxygen uptake may be of value not only to clients looking for more energy, but also for clients trying to lose weight and athletes looking for a competitive edge.
Decreased CO2 levels lower pain thresholds cause adrenalin to be released into the blood. As CO2 continues to drop, cells produce lactic acid to reduce alkalinity causing fatigue, numbness, tingling and anesthesia. Low CO2 also stimulates the smooth muscle to contract, constricting blood vessels, particularly to the heart and brain. Low CO2 also causes mast cells to release histamine and other mediators causing further blood vessel constriction. Adequate CO2 helps maintain blood pH at 7.4 and represents the reserve of alkali readily available for the neutralization of acids.
Figure 8 shows 87.5% of the subjects having an average drop of 3.125 in their sodium levels in their sodium levels. The improvement in kidney function rules out kidney dysfunction as a cause for the drop. Thus Magnesium Di-Potassium EDTA may be beneficial for those looking to lower sodium values.
In addition, 69% of the subjects had a drop of an average of 47 points in their triglycerides, 56.25% had a drop of an average of 3.9 in their calcium levels while those whose calcium increased, only did so by on average 1.7. Aside from the traditional interpretation, normalization of triglycerides is also associated with an improvement in glucose control and as Magnesium Di-Potassium EDTA may be beneficial for those with dysinsulinism (syndrome X).
Chelation by suppository with Magnesium Di-Potassium EDTA in suppository form is both safe and effective and represents a valid alternative to intravenous chelation with Di-sodium EDTA. In addition, Magnesium Di-Potassium EDTA also has shown to have certain beneficial effects not associated with the traditional Di-sodium form of EDTA.
1 The effect of EDTA chelation therapy and supportive multivitamin/trace mineral supplementation upon renal function. A study in Serum Creatine. E.W. McDonagh, DO, C.J. Rudolph, PhD, DO, and E. Cheraskin, MD, DMD .
2 Balancing body chemistry with nutrition seminars. Third Revision – January 2000 page 39.
The following is a letter from Dr. Halstead, considered by many to be the father of modern chelation
An Open Letter To Whom It May Concern
31 May 2000
I have been involved in the development of the EDTA suppositories since the idea was first conceived seven years ago. The suppository delivery system was developed because it meets a special need. The primary purpose was to produce a drug delivery system that was painless and effective for children and for adults that found it difficult to take chelation therapy because of time constraints.
Research studies showed that the uptake of EDTA was effective by the colonic route. The low molecular weight of EDTA of 292.1 facilitates efficient absorption through the colon wall. Moreover, there is an additional safety factor because it is in a special time release formulation. There is clinical evidence available that the suppository is not only safe, but it is effective. It is my professional opinion that approximately 90% or more of the EDTA is absorbed through the colon. For additional information on this subject it will be helpful to review my book, The Scientific Basis of EDTA Chelation Therapy, by Halstead and Rozema 1977.
Keep up the good work.
Bruce W. Halstead, M.D.